NPI 1699914358: Open Payments
NPI 1699914358. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$417 in 16 payments from 11 companies in 2025. Trend: 2023 $416 · 2024 $593 · 2025 $417
Food & beverage: $417
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $114 |
| Novo Nordisk Inc | 5 | $92 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $49 |
| Tactile Systems Technology Inc | 1 | $34 |
| ABBVIE INC. | 1 | $24 |
| TMS NeuroHealth Centers Inc. | 1 | $21 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $19 |
| Medtronic, Inc. | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
Products named: BREZTRI, Ozempic, Kerendia, Flexitouch Plus, QULIPTA, Rybelsus, TMS NeuroHealth Centers Inc., JOURNAVX.
